Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.
Follow-Up Questions
Qui est le CEO de Nemaura Medical Inc ?
Dr. Dewan Chowdhury est le Chairman of the Board de Nemaura Medical Inc, il a rejoint l'entreprise depuis 2009.
Quelle est la performance du prix de l'action NMRD ?
Le prix actuel de NMRD est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Nemaura Medical Inc ?
Nemaura Medical Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Nemaura Medical Inc ?
La capitalisation boursière actuelle de Nemaura Medical Inc est de $40.35
Est-ce que Nemaura Medical Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Nemaura Medical Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
